top of page

June 2020 // Communication

Updated: Mar 19, 2021

Synendos Therapeutics received a prestigious European grant (SME Instrument Phase I, TWO-BIRDS project ) that helped the company to head towards clinical trials. The European commission is now reporting about the results and the perspectives to treat post-traumatic stress disorder (PTSD) and other neuropsychiatric diseases. Read the full article here.



Recent Posts

See All

July 2023 // Communication

Synendos Therapeutics AG announces that co-founder and Scientific Advisor Board member, Professor Jürg Gertsch, presented groundbreaking...

Comments


bottom of page